N K Kim1, B O Choi, W S Jung, Y J Choi, K G Choi. 1. Department of Neurology and Ewha Medical Research Center, College of Medicine, Ewha Womans University, Jongro-gu, Seoul, South Korea.
Abstract
OBJECTIVE: To evaluate whether hyperhomocysteinemia is an independent risk factor for silent brain infarction (SBI), and to determine the relationship between homocysteine and folate in each type of methylenetetrahydrofolate reductase (MTHFR) polymorphism, in order to identify a way of reducing the risk for SBI. METHODS: The authors enrolled 161 patients with SBI and 126 healthy people, checked their fasting homocysteine and folate levels, and analyzed for the MTHFR C677T polymorphism. RESULTS: The mean plasma homocysteine level in patients with SBI (12.17 +/- 5.35 micro mol/L) was significantly higher than in normal healthy people (9.37 +/- 4.11 micro mol/L; p < 0.05). By subgroup analysis, based on the classification of plasma homocysteine levels as high (>or=11.77 micro mol/L), moderate (8.71 to 11.76 micro mol/L), and low (<or=8.70 micro mol/L), the adjusted OR (AOR) of the high group for SBI was significantly greater than that of the low group (AOR, 4.78; 95% CI, 2.45 to 9.33). The homocysteine level showed a significant inverse correlation with folate level only in patients with SBI with the MTHFR 677TT genotype (p < 0.05). CONCLUSIONS: This study demonstrates that hyperhomocysteinemia is an independent risk factor for SBI, and provides the possibility of reducing the risk for SBI in the MTHFR 677TT genotype by folate supplementation.
OBJECTIVE: To evaluate whether hyperhomocysteinemia is an independent risk factor for silent brain infarction (SBI), and to determine the relationship between homocysteine and folate in each type of methylenetetrahydrofolate reductase (MTHFR) polymorphism, in order to identify a way of reducing the risk for SBI. METHODS: The authors enrolled 161 patients with SBI and 126 healthy people, checked their fasting homocysteine and folate levels, and analyzed for the MTHFRC677T polymorphism. RESULTS: The mean plasma homocysteine level in patients with SBI (12.17 +/- 5.35 micro mol/L) was significantly higher than in normal healthy people (9.37 +/- 4.11 micro mol/L; p < 0.05). By subgroup analysis, based on the classification of plasma homocysteine levels as high (>or=11.77 micro mol/L), moderate (8.71 to 11.76 micro mol/L), and low (<or=8.70 micro mol/L), the adjusted OR (AOR) of the high group for SBI was significantly greater than that of the low group (AOR, 4.78; 95% CI, 2.45 to 9.33). The homocysteine level showed a significant inverse correlation with folate level only in patients with SBI with the MTHFR 677TT genotype (p < 0.05). CONCLUSIONS: This study demonstrates that hyperhomocysteinemia is an independent risk factor for SBI, and provides the possibility of reducing the risk for SBI in the MTHFR 677TT genotype by folate supplementation.
Authors: In Bo Han; Ok Joon Kim; Jung Yong Ahn; Doyeun Oh; Sun Pyo Hong; Ryoong Huh; Sang Sup Chung; Nam Keun Kim Journal: Yonsei Med J Date: 2010-02-12 Impact factor: 2.759
Authors: Pınar Aslan Koşar; Muhammet Yusuf Tepebaşı; Nihat Şengeze; İlter İlhan; Halil İbrahim Büyükbayram; Süleyman Kutluhan Journal: Mol Biol Rep Date: 2021-05-21 Impact factor: 2.316
Authors: Yunkyung Cho; Jung O Kim; Jeong Han Lee; Hye Mi Park; Young Joo Jeon; Seung Hun Oh; Jinkun Bae; Young Seok Park; Ok Joon Kim; Nam Keun Kim Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240
Authors: Ok Joon Kim; Sun Pyo Hong; Jung Yong Ahn; Seung Ho Hong; Tae Sun Hwang; Soo Ok Kim; Wangdon Yoo; Doyeun Oh; Nam Keun Kim Journal: Yonsei Med J Date: 2007-04-30 Impact factor: 2.759
Authors: Roshan Ariyaratnam; Juan P Casas; John Whittaker; Liam Smeeth; Aroon D Hingorani; Pankaj Sharma Journal: PLoS Med Date: 2007-04 Impact factor: 11.069